Patient Cases on Benefits from Anti-Arrhythmic Drugs

Description

This activity was planned for clinicians to be able to select guideline-driven antiarrhythmic drugs (AADs) in specific cases of atrial fibrillation (AF), recognizing safe medication considerations. It is part of the Early Onset of Atrial Fibrillation & the Contemporary Use of Antiarrhythmic Drugs.

Learner Objectives
Upon completion of this activity, you should be able to:

Identify patients who would benefit from anti-arrhythmic drugs as a part of a larger rhythm control treatment plan.

Target Audience
The primary target audience is general cardiologists and electrophysiologists, as well as other members of the CV team including nurse practitioners, physician assistants and pharmacists. In addition, general practitioners and other specialists who manage AF patients will benefit from the education and will be provided with opportunities to access the education.

Important Dates
Date of Release: October 24,2024
Term of Approval/Date of Expiration: November 3, 2025

Faculty

Jonathan P. Piccini, Sr., MD, FACC

Duke University Medical Center

Durham, NC

Disclosures

Consultant Fees/Honoraria: Abbot, Abbvie, Biotronik, ElectroPhysiology Frontiers,
Medtronic, Milestone, Philips, Sanofi Aventis

Acknowledgement
Educational grant support provided by: Sanofi

Summary


Availability:	On-Demand
	Expires on Nov 03, 2025


Cost:	FREE


Credit Offered:	No Credit Offered